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Background: Metabolic factors have been reported to increase the prevalence of colorectal adenomas, however,
whether metabolic factors might also accelerate the recurrence after removal of adenomas has not yet been
discussed. In this retrospective multicenter study, we clarified the risk factors for adenoma recurrence focusing
on metabolic factors.
Methods: We analyzed the medical records of 43,195 patients who had undergone colonoscopy between January
2005 and December 2011 at 5 hospitals in Japan. Of these, the data of 1111 patients who had undergone removal
of adenomas at the first screening colonoscopy, and then been followed up by colonoscopy 1 year and 2 years
later were analyzed.
Results: The following 8 factors were demonstrated with a multivariate analysis as being associated with colorectal
adenomas recurrence: for adenoma-related factors, 5 factors (villous features, grade of dysplasia, location and size of
the largest removed adenoma, and number of the removed adenomas) were identified; for metabolic factors and other
factors, 3 factors (age, body mass index (BMI), and fasting blood glucose (FBG)) were identified. A risk score (0–10
points) was developed based on these 8 factors. The risk of adenoma recurrence increased as the risk score increased.
When the risk score was ≥3 (3–10) points, the odds ratio relative to <3 (0–2) points was 7.07 (95% CIs 5.30–9.43).
Conclusions: In addition to adenoma-related factors (villous features, grade of dysplasia, location, size and number),
3 factors (age, BMI and FBG) were demonstrated to influence the recurrence rate of colorectal adenoma. When the risk
score was ≥3, the risk of recurrence was significantly elevated.
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Despite the recent advances in therapeutic modalities for
colorectal cancer (CRC), it remains a major cause of
mortality worldwide [1]. In most cases, CRC develops
through the adenoma–carcinoma sequence, which serves
as the rationale for screening and prevention of CRC by
colonoscopic examinations. Colonoscopy with removal of
adenomas is a powerful tool to reduce the mortality of
CRC [1-3]. Surveillance colonoscopy is also recommended* Correspondence: nakajima-tky@umin.ac.jp
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unless otherwise stated.after the initial endoscopic removal of adenoma, because
of the possibility of development of new tumors [2,3].
In Japan, no guidelines have been established yet for
surveillance colonoscopies. However, in the United States,
the American Gastroenterological Association (AGA)
guidelines are adopted as the basic protocols for colo-
noscopic surveillance after initial screening/removal of
adenomas. These guidelines recommend stratification
of patients at the time of the initial colonoscopy into
groups at a low and high risk of subsequent development
of more advanced tumors [2]. Patients who have advanced
adenomas or multiple (3 or more) adenomas are classified
into the high-risk group. Advanced adenomas are defined
as adenomas that show high-grade dysplasia or >20%
villous component or measure ≥1 cm in size. Follow-upral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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risk group. Patients with other adenomas, namely, 1 or 2
small (<1 cm) tubular adenomas that do not show high-
grade dysplasia, are classified into the low-risk group, and
follow-up colonoscopy every 5–10 years is recommended
for this group. In patients with hyperplastic polyps and
those with only average risk, follow-up colonoscopy every
10 years is considered adequate.
Recently, in some studies, metabolic factors were shown
to be associated with an increased prevalence of colorectal
tumors. Limburg et al. and Elwing et al. demonstrated
the association between diabetes mellitus and colorectal
tumors [4,5]. Otani et al. and Liu et al. showed a rela-
tionship between dyslipidemia and colorectal tumors
[6,7]. Kim et al. and Orranapalai et al. proved that
metabolic syndrome was associated with colorectal
tumors [8,9]. The incidence rates of metabolic factors
have dramatically increased in developed countries as a
result of the high prevalence of obesity [10]. Therefore,
metabolic factors rank as important risk factors for the
increase of prevalence of colorectal tumors. Metabolic
factors have also been suggested as risk factors for
recurrence after endoscopic removal of colorectal aden-
omas. To the best of our knowledge, however, no study
as yet has discussed whether the presence of metabolic
factors might accelerate the development of recurrence
after endoscopic removal of colorectal adenomas.
The aim of this study was to identify the risk factors for
colorectal adenoma recurrence, focusing on metabolic
factors, in addition to those adenoma-related factors
that the AGA guidelines have established. We therefore
constructed a scoring system with the identified risk
factors for recurrence that could predict the recurrence
rate according to the risk score.
Methods
Study participants
This multicenter retrospective study was conducted with
the participation of 5 community hospitals in Japan, in-
cluding Chigasaki Municipal Hospital, Yokohama Rousai
Hospital, Tokyo Metropolitan Hiroo Hospital, Machida
Municipal Hospital, and NTT Medical Center Tokyo.
We analyzed the medical records of 43,195 patients who
had undergone colonoscopy between January 2005 and
December 2011 at any one of the 5 hospitals. Among these,
only those who had undergone complete colonoscopy
for the purpose of screening were enrolled in this study
(n = 32,566); the remaining 10,629 patients were excluded
either because they had undergone colonoscopy for diag-
nostic purposes, or did not undergo complete colonoscopy.
Next, 24,123 subjects who had not undergone removal
of adenomas ≥5 mm in size at the time of the screening
colonoscopy were excluded, and the remaining 8443
subjects who had undergone removal of adenomas ≥5 mmin size were included in this study (smaller adenomas have
been shown to be of minimal clinical significance [11]).
Furthermore, from among the 8443 subjects, we excluded
6703 subjects who did not undergo surveillance colonos-
copy at 1 year and 2 years after the initial colonoscopy
(that is, all the eligible patients enrolled in this study
had undergone colonoscopy 3 times; colonoscopy is very
cheap in Japan, and annual surveillance colonoscopies are
common). To be eligible for this study, the participants
had to have undergone complete colonoscopy at all the
three examinations. A complete colonoscopy was consid-
ered to include: colonoscopy up to the level of the cecum,
good bowel preparation, and removal of all the detected
adenomas. Thereafter, further participants were excluded
for the following reasons (total n = 629): no history or no
laboratory data available (n = 327); age less than 50 years
old or greater than 85 years old (n = 120); history of colo-
rectal resection or appendectomy (n = 88); history of
removal of carcinoma (n = 28); history of inflammatory
bowel disease (IBD), familial adenomatous polyposis (FAP)
or hereditary non-polyposis colorectal cancer (HNPCC)
(n = 18); history of regular use or use for over 7 days a
month of aspirin or non-aspirin steroidal anti-inflammatory
drugs (NSAIDs) (n =31); and patients with a life expectancy
of less than 2 years because of severe diseases such as
cancer, severe liver dysfunction, severe renal dysfunction,
severe infection, etc. (n = 17); Finally, 1111 participants
were included for the analysis in our study (Figure 1). To
minimize the selection bias, all of the patients who had
undergone colonoscopy at the 5 hospitals over the 7-year
period were assessed, and all of the patients who fulfilled
the inclusion criteria but not the exclusion criteria were
enrolled in this study.
The study protocol was approved by the individual
ethics committees of each of the 5 participating hospi-
tals, that are Chigasaki Municipal Hospital, Yokohama
Rousai Hospital, Tokyo Metropolitan Hiroo Hospital,
Machida Municipal Hospital, and NTT Medical Center
Tokyo.
Data collection
A total of 20 data points at the initial colonoscopy and
colorectal adenoma recurrence over the 2-year observation
period were obtained from the medical records. The 20
items evaluated were: age at initial colonoscopy, gender,
body mass index (BMI), current alcohol consumption,
current cigarette smoking, the present history of hyper-
tension, diabetes mellitus and dyslipidemia, fasting blood
glucose (FBG), hemoglobin A1c (HbA1c), serum total
cholesterol (TC), high-density lipoprotein cholesterol
(HDL-C), low-density lipoprotein cholesterol (LDL-C)
and triglycerides (TG), morphology/villous features/
grade of dysplasia/location/size of the largest removed
adenoma, and number of removed adenomas.
Participants who underwent colonoscopy from Jan. 2005 
to Dec. 2011 at any of the 5 participant hospitals (n = 
43195)
Participants excluded because they underwent 
colonoscopy for diagnostic purposes or did not 
undergo complete colonoscopy (n = 10629)
Asymptomatic participants who underwent complete 
colonoscopy for screening (n = 32566)
Participants who underwent removal of adenomas (5 mm 
or larger in size) (n = 8443)
Participants who did not undergo adenoma removal at 
the time of the initial colonoscopy (n = 24123)
Participants excluded because they had not undergone 
surveillance colonoscopy at 1 year and 2 years after 
the initial colonoscopy (n = 6703)
Participants were also excluded for
the following reaons: (n = 629)
- insufficient history or laboratory data (n = 327)
- age < 50 or > 85 years (n = 120)
- previous history of colorectal resection
or appendectomy (n = 88)
- removal of carcinoma (n = 28)
- IBD, FAP, HNPCC (n = 18)
- Aspirin or NSAIDs use (n = 31)
- life expectancy less than 2 years
because of severe disease (n = 17)
Participants eligible for analysis in this study
(n = 1111)
Figure 1 Inclusion and exclusion criteria of the study participants.
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tumors increased in adults aged 65 and older [1]. So, age
was categorized into ≥65 and <65. BMI was calculated
as the weight (in kg) divided by height squared (in m2).
Obesity was defined as BMI ≥25 [12]. BMI was classified
into ≥25 and <25. Current alcohol intake history was
defined as positive when the consumption was estimated
to be in excess of 30 g/day. Present history of hyper-
tension was defined as blood pressure ≥130/85 mmHg
and/or current use of antihypertensive medication [13].
Present history of diabetes mellitus was diagnosed if the
patients had a random glucose level of ≥200 mg/dl, FBG
of ≥126 mg/dl, HbA1c of ≥6.5% or were taking antidia-
betic medication [14]. Present history of dyslipidemia was
defined as TG ≥150 mg/dl and/or HDL-C <40 mg/dl or
were taking antidyslipidemic medication [13]. The FBG,
HbA1c, TC, HDL-C, LDL-C, and TG were determined by
laboratory testing at the time of the initial colonoscopy.
FBG, HbA1c, HDL-C, and TG were classified into two
groups with the above cutoff values. TC ≥220 and
LDL ≥ 140 were adopted as cutoff values according to
the Japanese definition [15]. For the largest among the
removed adenomas at the time of the initial colonoscopy,
we determined the presence/absence of >20% villous
components, grade of dysplasia (high/low), location, and
size. The location of the largest adenoma was classified
as right-sided if it was in the cecum, ascending colon ortransverse colon, and as left-sided if it was in the splenic
flexure, descending colon, sigmoid colon or rectum. Colo-
rectal adenoma recurrence was diagnosed if an adenoma
(s) ≥5 mm in size was found in the surveillance colonos-
copy, and both newly developed colorectal adenomas and
colorectal adenomas recurring at the same location as that
of the previously removed adenoma were included.
Statistical analysis
Statistical analysis was conducted using the JMP 10.0
software. Chi-square analysis was used to compare dif-
ferences in variables. Univariate analysis was performed
by logistic regression analysis. Multivariate analysis was
performed by multiple logistic regression analysis. The
correlation between the risk score and colorectal aden-
oma recurrence were assessed by analysis of the receiver
operating characteristic (ROC) curves. Differences were
considered statistically significant at p <0.05.
Results
Baseline characteristics and recurrence of colorectal
adenomas
The baseline clinical characteristics of the study partici-
pants with and without colorectal adenoma recurrence
developing within 2 years of the initial colonoscopy are
provided in Table 1 and clinical characteristics of the
removed adenomas are shown in Table 2.
Table 1 Clinical characteristics of the study participants
(n = 1111)
Parameters Recurrence P value
Present (%) Absent (%)
Total 471 (42.4) 640 (57.6)
Age (years) 0.808
≥65 275 (58.4) 369 (57.7)
<65 196 (41.6) 271 (42.3)
Gender 0.106
Male 370 (78.6) 476 (74.4)
Female 101 (21.4) 164 (25.6)
BMI (kg/m2) <0.001
≥25 142 (30.1) 115 (18.0)
<25 329 (69.9) 525 (82.0)
Current alcohol consumption 0.407
Yes 265 (56.3) 376 (58.8)
No 206 (43.7) 264 (41.3)
Current cigarette smoking 0.011
Yes 174 (36.9) 190 (29.7)
No 297 (63.1) 450 (70.3)
Hypertension 0.019
Yes 280 (59.4) 335 (52.3)
No 191 (40.6) 305 (47.7)
Diabetes Mellitus <0.001
Yes 149 (31.6) 129 (20.2)
No 322 (68.4) 511 (79.8)
Dyslipidemia 0.001
Yes 172 (36.5) 176 (27.5)
No 299 (63.5) 464 (72.5)
FBG (mg/dL) <0.001
≥126 135 (28.7) 82 (12.8)
<126 336 (71.3) 558 (87.2)
HbA1c (%) <0.001
≥6.5 109 (23.1) 71 (11.1)
<6.5 362 (76.9) 569 (88.9)
TC (mg/dL) 0.080
≥220 99 (21.0) 108 (16.9)
<220 372 (79.0) 532 (83.1)
HDL-C (mg/dL) 0.176
<40 56 (11.9) 60 (9.4)
≥40 415 (88.1) 580 (90.6)
LDL-C (mg/dL) 0.010
≥140 73 (15.5) 66 (10.3)
<140 398 (84.5) 574 (89.7)
TG (mg/dL) <0.001
≥150 153 (32.5) 127 (19.8)
<150 318 (67.5) 513 (80.2)
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471 of the 1111 patients (42.4%) were identified as having
recurrence of colorectal adenomas whereas the remaining
640 patients (57.6%) were free of recurrence (Table 1). Of
the 471, the recurrence was identified at the 1-year
surveillance colonoscopy in 313 patients (28.2%), and at
the 2-year surveillance colonoscopy in the remaining
158 patients (14.2%).
The characteristics of recurrent adenomas are demon-
strated in Table 3. Among recurrent adenomas, advanced
adenomas occupied 10.8% (51/471). Location of the largest
recurrent adenomas tended to exist in the right-sided colon.
Univariate analysis to identify the risk factors for adenoma
recurrence
Each of 20 risk factors evaluated was found to be statisti-
cally significant, except for the age, gender, current alcohol
consumption, TC and HDL-C. Although older males were
more likely to undergo adenoma removal at the time of
the initial colonoscopy, age and gender were not identified
as statistically significant factors influencing the risk of
colorectal adenoma recurrence. While current alcohol
consumption was not found to be statistically significant,
current cigarette smoking was statistically significant.
Metabolic factors such as the BMI, hypertension, diabetes
mellitus and dyslipidemia were found to be statistically
significant factors, as were the FBG, HbA1c, LDL-C and
TG. Among the metabolic factors, TC and HDL-C were
not statistically significant. In regard to the adenoma-
related factors, non-polypoid lesion, presence of >20%
villous components, presence of high-grade dysplasia, a
larger maximum diameter and a larger number of removed
adenomas were found to be statistically significant risk
factors for colorectal adenoma recurrence. Right-sided
adenomas were associated with a higher risk of recurrence
than left-sided adenomas. The odds ratio and p value of
each factor with univariate analysis are shown in Table 4.
Multivariate analysis to identify independent risk factors
for adenoma recurrence
Multiple logistic regression analysis was performed with
15 of 20 risk factors. There was collinearity among a
present history of diabetes mellitus, FBG and HbA1c.
Among these 3 factors, FBG was used in the multivariate
analysis because the odds ratios of FBG were maximum
among these in the univariate analysis. There was also
collinearity among a present history of dyslipidemia, TC,
HDL-C, LDL-C and TG. The odds ratios of LDL-C and
TG were greater than that of others, and the correlation
coefficient between LDL-C and TG was low (correlation
coefficient = 0.0992). So, among these factors, LDL-C
and TG were used in the multivariate analysis.
The results from the multivariate analysis identified 7
factors, namely, age, BMI, FBG, dysplasia grade/location/
Table 2 Clinical characteristics of the removed adenomas (n = 1111)
Parameters Recurrence P value
Present (%) Absent (%)
Total 471 (42.4) 640 (57.6)
Morphology of the largest adenoma <0.001
Non-polypoid lesion 79 (16.8) 48 (7.5)
Polypoid lesion 392 (83.2) 592 (92.5)
>20% Villous features of the largest adenoma <0.001
Yes 178 (37.8) 145 (22.7)
No 293 (62.2) 495 (77.3)
Degree of differentiation of the largest adenoma <0.001
high grade 199 (42.3) 114 (17.8)
low grade 272 (57.7) 526 (82.2)
Location of the largest adenoma 0.028
Right-sided colon 250 (53.1) 297 (46.4)
Left-sided colon 221 (46.9) 343 (53.6)
Diameter of the largest adenoma (mm) <0.001
≥10 300 (63.7) 161 (25.2)
<10 171 (36.3) 479 (74.8)
Number of the removed adenomas
≥3 320 (67.9) 121 (18.9) <0.001
<3 151 (32.1) 519 (81.1)
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adenomas as being statistically significant factors influen-
cing the risk of colorectal adenoma recurrence. Villous
features were almost statistically significant (p = 0.063).
The odds ratio and p value of each factor from the multi-
variate analysis are shown in Table 5.
Scoring system for calculating the recurrence rate of
colorectal adenomas
Analysis was performed using 8 factors (Table 5): For
adenoma-related factors, 5 factors, namely, villous features/Table 3 Characteristics of recurrent adenomas (n = 471)
Number of recurrent adenomas, median [interquartile range] 1 [1-2]




Non-polypoid lesion 20 (4.2)
Polypoid lesion 451 (95.8)
Pathology (%)
Advanced adenoma 51 (10.8)
Non-advanced adenoma 420 (89.2)
Location of the largest adenoma (%)
Right-sided colon 290 (61.6)
Left-sided colon 191 (38.4)grade of dysplasia/location/size of the largest adenoma,
and number of the removed adenomas were included. For
metabolic factors and other factors, 3 factors, namely, age,
BMI, FBG were included. Seven of 8 factors were adopted
because they were statistically significant in the multi-
variate analysis. Villous features were included because it
was an established risk factor in the AGA guidelines, and
was also nearly statistically significant in our study in the
multivariate analysis including metabolic risk factors.
One point was scored for if each positive factor. But,
because the odds ratio of the number of removed aden-
omas in the multivariate analysis was almost 3 times
bigger than that of other factors, the number of removed
adenomas counted as 3 points if it was positive. The risk
score was calculated by summing up each individual
score, and ranged from 0 to 10 points.
The correlation between the risk score (0–10 points)
and colorectal adenoma recurrence during the 2-year
follow-up after the initial colonoscopy was analyzed with
a logistic regression analysis, which revealed a statisti-
cally significant correlation (p <0.001).
ROC curve analysis revealed an AUROC for colorectal
adenoma recurrence of 0.80 (Figure 2). The sensitivity,
specificity, positive predictive value (PPV) and negative
predictive value (NPV) for each risk score were calculated
(Table 6). The recurrence rate of colorectal adenomas
during the 2-year follow-up period after the initial
Table 4 Univariate analysis of risk factors for colorectal
adenoma recurrence
Factor OR (95% CI) p value
*Age ≥65 1.03 (0.81-1.31) 0.808
*Gender; Male 1.26 (0.95-1.67) 0.106
*BMI ≥25 kg/m2 1.97 (1.49-2.61) <0.001
*Current alcohol consumption; Yes 0.90 (0.71-1.15) 0.407
*Current cigarette smoking; Yes 1.39 (1.08-1.79) 0.011
*Hypertension; Yes 1.33 (1.05-1.70) 0.019
Diabetes Mellitus; Yes 1.83 (1.39-2.41) <0.001
Dyslipidemia; Yes 1.52 (1.17-1.96) 0.001
*FBG ≥126 mg/dl 2.73 (2.01-3.71) <0.001
HbA1C ≥6.5 % 2.41 (1.74-3.35) <0.001
TC ≥220 mg/dl 1.31 (0.97-1.78) 0.080
HDL-C <40 mg/dl 1.30 (0.89-1.92) 0.176
*LDL-C ≥140 mg/dl 1.60 (1.12-2.28) 0.010
*TG ≥150 mg/dl 1.94 (1.48-2.56) <0.001
*Morphology of the largest
adenoma; Non-polypoid lesion
2.49 (1.70-3.64) <0.001
* > 20% Villous features of
the largest adenoma; Yes
2.07 (1.59-2.70) <0.001
*Degree of differentiation of
the largest adenoma; high grade
3.38 (2.57-4.43) <0.001
*Location of the largest adenoma;
Right-sided colon
1.31 (1.03-1.66) 0.028
*Diameter of the largest adenoma ≥10 mm 5.22 (4.03-6.76) <0.001
*Number of the removed adenomas ≥3 9.09 (6.89-11.99) <0.001
*Risk factors that were used in multivariate analysis.
Table 5 Multivariate analysis of risk factors for colorectal
adenoma recurrence
Factor OR (95% CI) p value
*Age ≥65 1.38 (1.01-1.89) 0.045
Gender; Male 1.00 (0.69-1.44) 0.999
*BMI ≥25 kg/m2 1.70 (1.19-2.44) 0.003
Current alcohol consumption;Yes 0.97 (0.69-1.36) 0.870
Current cigarette smoking; Yes 1.20 (1.08-1.79) 0.288
Hypertension; Yes 1.24 (0.91-1.68) 0.169
*FBG ≥126 mg/dl 2.04 (1.40-2.98) <0.001
LDL-C ≥140 mg/dl 1.37 (0.86-2.15) 0.181
TG ≥150 mg/dl 1.29 (0.90-1.83) 0.159
Morphology of the largest adenoma;
Non-polypoid lesion
1.06 (0.58-1.54) 0.825
* > 20% Villous features of the largest
adenoma; Yes
1.56 (0.98-2.52) 0.063
*Degree of differentiation of the
largest adenoma; high grade
2.40 (1.51-3.83) <0.001
*Location of the largest adenoma;
Right-sided colon
1.43 (1.06-1.94) 0.018
*Diameter of the largest adenoma ≥10 mm 2.89 (2.07-4.04) <0.001
*Number of the removed adenomas ≥3 6.12 (4.52-8.34) <0.001
*Risk factors that were adopted in our scoring system.
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recurrence and the total number of cases for each score
are also shown in Table 6. When the cutoff value for the
risk score was set at 3, the odds ratio of ≥3 points (3–10
points) relative to <3 points (0–2 points) for adenoma
recurrence was determined to be 7.07 (95% CI 5.30–9.43).
In those cases where the risk score was ≥3 (3–10) points,
the colorectal adenoma recurrence rate during the 2-year
period was 59.8%, and the sensitivity, specificity, PPV and
NPV of the detection of adenoma recurrence were deter-
mined to be 83.2%, 58.8%, 59.8% and 82.6%, respectively
(Table 7).Discussion
As suggested by the AGA guidelines, we confirmed with
a multivariate analysis in this study that advanced aden-
omas or the presence of ≥3 adenomas were associated
with an increased risk of colorectal adenoma recurrence
[2] (note that villous features were nearly statistically
significant). Furthermore, our multivariate analysis also
revealed that age, 2 metabolic factors (elevated BMI,increased FBG) and adenomas in the right-sided colon at
the initial colonoscopy were associated with an increased
risk of colorectal adenoma recurrence.
Age and gender have been reported as risk factors for
the prevalence of colorectal tumors [1]. Zauber et al. dem-
onstrated that the presence of colorectal adenomas was
higher in men and among elderly people [3]. However, age
and sex still remain controversial from the point of view
of the risk of recurrence of adenomas [2]. In our study,
age was also identified as a risk factor of recurrence, while
sex was not statistically significant for recurrence.
Among patients in whom colorectal adenomas were
removed at the time of the initial colonoscopy, the esti-
mated recurrence rate at surveillance colonoscopy per-
formed within 3–4 years has been reported as 15–60%
[16,17]. In Japan, Yamaji et al. estimated a colorectal
tumor recurrence rate of 7.2% per year in cases with no
initial tumors, 19.3% per year in those with small aden-
omas, and 22.9% per year in those with advanced lesions
[18]. In our study, the recurrence rate during a 2-year
follow-up period after the initial screening colonoscopy
was 42.4%, being largely consistent with previous reports.
At the time of surveillance colonoscopy, it is often
difficult to differentiate between actual recurrence and
detection of an adenoma missed in the earlier examin-
ation. On the other hand, from the clinical standpoint,
strict differentiation between the two is not always
necessary. Irrespective of whether the lesions identified
Figure 2 ROC curve for the risk score and recurrence. The AUROC for recurrence was determined to be 0.80 from ROC analysis.
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lesions, the lesions need to be removed. In our study, the
recurrence rate at the 1-year surveillance colonoscopy was
28.2%, while that at the 2-year surveillance colonoscopy
was 14.2%. This is possibly because of a substantial reduc-
tion of the miss rate resulting from the 2-year surveillance
colonoscopy having been conducted after 2 earlier colon-
oscopies (initial and at 1 year). For the same reason, the
recurrence rate at the 2-year surveillance colonoscopy
(14.2%) is more likely to be closer to the actual recurrence
rate per year. This rate is largely consistent with the rateTable 6 ROC analysis for the risk score and recurrence rate (n












aRecurrence rate during the 2-year period after the initial colonoscopy (%) (numberreported by Yamaji et al. [18]. Furthermore, the difference
in the recurrence rate between the 1-year and 2-year
follow-up colonoscopies was 14.0% (=28.2%–14.2%), which
may correspond to the miss rate of detection. Rex et al.
reported that the miss rate for adenomas ≥10 mm in
diameter was 6%, for adenomas 6–9 mm in diameter
was 13%, and for adenomas ≤5 mm in diameter was
27% [19]. Pickhardt et al. reported from their virtual
colonoscopy study that conventional colonoscopy failed
to detect 12% of lesions ≥10 mm in diameter [20]. Our
results were consistent with these miss rates.=1111)
PPV (%) NPV (%) Recurrence ratea
42.4 100.0 7.5 (6/80)
45.1 92.5 16.4 (30/183)
51.3 86.3 22.4 (43/192)
59.8 82.6 29.2 (35/120)
66.6 80.2 50.0 (57/114)
71.1 75.2 54.6 (72/132)
78.6 70.4 68.6 (70/102)
84.0 66.1 79.0 (79/100)
89.8 61.7 88.1 (59/67)
95.2 58.6 93.8 (15/16)
100.0 57.9 100.0 (5/5)
of cases showing recurrence/total number of cases, for each risk score).
Table 7 Cutoff value of the risk score for predicting





0–2 79 376 455
3–10 392 264 656
The odds ratio was 7.07 (95% CI 5.30–9.43) (0–2 vs. 3–10).
The recurrence rate for the risk score 3–10 was 59.8% (392/656).
The sensitivity, specificity, PPV and NPV of a risk score 3–10 for the prediction
of recurrence were 83.2%, 58.8%, 59.8% and 82.6%, respectively.
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with increased levels of metabolic factors is visceral fat
deposition. Visceral fat deposition is known to be associ-
ated with insulin resistance, hyperinsulinemia and high
levels of IGF I, which are thought to influence carcinogenic
processes by increasing the cell proliferative activities and
reducing apoptosis [8,21]. Obesity-related inflammation
and oxidative stress are also thought to increase the risk of
development of colorectal tumors [22]. Visceral adipose
tissue is considered to be an endocrine tissue, as it releases
some inflammatory cytokines such as C-reactive protein,
tumor necrosis factor, interleukin-6, and some adipocyto-
kines such as leptin and adiponectin [23]. These cytokines
and adipocytokines are considered to increase the risk of
development, as well as the growth, of colorectal tumors.
These may be the mechanisms underlying the reported
increased prevalence of colorectal adenoma associated with
metabolic factors. In this study, we demonstrated with the
multivariate analysis that BMI was associated with the risk
of recurrence of colorectal adenomas.
Diabetes mellitus is known to be associated with an
increased prevalence of CRC [4], although its associ-
ation with the prevalence of colorectal adenomas has
not yet been sufficiently investigated. Nevertheless,
among patients with obesity, a strong correlation has
been reported between the presence of adenomas and
diabetes mellitus [5]. Three factors, namely a present
history of diabetes mellitus, FBG and HbA1c, had col-
linearity. In our study, FBG was used in the multivariate
analysis, because its odds ratio was maximum in the
univariate analysis among these 3 factors. FBG then
remained as a statistically significant risk factor of colo-
rectal adenoma recurrence in the multivariate analysis.
Some studies have reported that metabolic factors may
be strongly associated with the presence of adenomas in
the right-sided colon and multiple (three or more) aden-
omas [8,24]. On the other hand, screening colonoscopy
has been found to confer less protection against future
development of CRC in the case of right-sided than left-
sided adenomas [16,25]. Poorer preparation and a more
unfavorable anatomic configuration of the right-sided
colon compromising the visibility of lesions are possible
reasons for the higher miss rates of adenomas in theright-sided colon than in the left-sided colon [16]. In our
study, location of the largest adenoma in the right-sided
colon was also identified as a risk factor for recurrence.
Therefore, endoscopists should pay particular attention
to the right side of the colon, both at the time of the
initial screening colonoscopy and at the time of the
surveillance colonoscopy. It must be emphasized here
that sigmoidoscopy is not adequate for surveillance after
removal of adenomas.
Our study demonstrated that the higher the risk score,
the higher the recurrence rate. ROC analysis revealed 3 as
the optimal cutoff value as the risk score for predicting
the risk of colorectal adenoma recurrence during the
2-year period from the initial colonoscopy, as it was
associated with a very high AUROC and sensitivity. In
those cases where the risk score was ≥3 points (3–10
points), the 2-year colorectal adenoma recurrence rate
was calculated to be 59.8% (sensitivity 83.2%). Therefore,
surveillance colonoscopy within 2 years may be a safe
option for these patients.
Our study had some limitations. We were unable to
obtain any waist circumference data. so it was impossible to
analyze the association between the presence/absence of
metabolic syndrome and colorectal adenoma recurrence.
Recently, colonoscopic quality indicators such as aden-
oma detection rates, withdrawal time and cecal intubation
time are proposed. But these data couldn’t be obtained
from medical records retrospectively. Each 5 hospitals
conduct 2000–6000 colonoscopies per year, and all of
colonoscopists in 5 hospitals were certified from Japan
gastroenterological endoscopy society. Then, recurrence
rate of adenoma of 5 hospitals ranged from 40.6% to
43.7% (p = 0.9766). There were no significant differences in
recurrence rate between 5 hospitals. So, the bias according
to the colonoscopists guess to be small.
Most of the participants of this study were followed up
for only 2 years after the initial screening colonoscopy; and
only a few patients were followed up for 3 years or more.
Therefore, we could not collect the 3-year surveillance data.
A recent study has suggested that the use of aspirin or
NSAIDs may be associated with a reduced prevalence of
adenomas, and probably cancer [26]. However, among
the participants who were eligible for analysis in this
study, only 31 were taking aspirin/NSAIDs, and they
were excluded from this study because the sample size
was too small to allow reasonable analysis.
Family history of CRC has been reported as a risk factor
for colorectal adenoma recurrence [2]. However, accord-
ing to the medical records, the number of patients with a
family history of CRC among the eligible participants was
insufficient to allow reliable statistical analysis. Therefore,
we did not include this factor in the analyses in our study.
Further prospective studies using larger sample sizes may
be warranted to determine the risk of colorectal adenoma
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as well as that associated with the above factors.
Conclusions
In addition to the risk factors included in the AGA guide-
lines, we demonstrated that age, BMI, FBG and adenomas
located in the right-sided colon were associated with an
increased risk of development of recurrent colorectal
adenomas after removal of adenomas at the initial col-
onoscopy. Based on this finding, we then constructed a
scoring system to predict the recurrence rate according
to our risk score.
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